Anti-adhesion material and substitute biomembrane using decellularized tissue

Patent metadata

Field	Value
Publication number	US-11033661-B2
Application number	US-201615556776-A
Country	US
Kind code	B2
Filing date	Mar 7, 2016
Priority date	Mar 12, 2015
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

An anti-adhesion material comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing an anti-adhesion material comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; an anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer or fibrin glue; a substitute biomembrane comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing a substitute biomembrane comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; and a substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer or fibrin glue.

First claim

The invention claimed is:

1. An anti-adhesion material comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol,
wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin,
wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and
wherein the anti-adhesion material reduces adhesion to biological tissues.

2. The anti-adhesion material of claim 1 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

3. The anti-adhesion material of claim 2 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

4. The anti-adhesion material of any one of claim 1 , claim 2 or claim 3 wherein the biocompatible polymer is a biocompatible polymer which naturally occurs.

5. The anti-adhesion material of any one of claim 1 , claim 2 or claim 3 wherein the biocompatible polymer is fibrin glue.

6. The anti-adhesion material of claim 1 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

7. The anti-adhesion material of any one of claim 1 , claim 2 , or claim 3 wherein the anti-adhesion material is an anti-adhesion membrane and a film thickness is 10 to 5,000 μm.

8. An anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the anti-adhesion material reduces adhesion to biological tissues.

9. The kit of claim 8 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

10. The kit of claim 9 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

11. The kit of any one of claim 8 , claim 9 or claim 10 wherein the biocompatible polymer is fibrin glue.

12. The kit of claim 8 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

13. The kit of any one of claim 8 , claim 9 , or claim 10 wherein the anti-adhesion material is an anti-adhesion membrane and a film thickness is 10 to 5,000 μm.

14. A substitute biomembrane comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the substitute biomembrane reduces adhesion to biological tissues.

15. The substitute biomembrane of claim 14 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

16. The substitute biomembrane of claim 15 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

17. The substitute biomembrane of any one of claim 14 , claim 15 or claim 16 wherein the biocompatible polymer is a biocompatible polymer which naturally occurs.

18. The substitute biomembrane of any one of claim 14 , claim 15 or claim 16 wherein the biocompatible polymer is fibrin glue.

19. The substitute biomembrane of claim 14 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

20. The substitute biomembrane of any one of claim 14 , claim 15 or claim 16 wherein a film thickness is 10 to 5,000 μm.

21. A method for preparing a substitute biomembrane comprising complexing a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, to decellularized tissues, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the substitute biomembrane reduces adhesion to biological tissues.

22. The method of claim 21 wherein the complexation is immersion or coating of the biocompatible polymer to the decellularized tissues.

23. A substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer selected from the group consisting of alginic acid, gelatin, fibrin glue and polyethylene glycol, wherein the decellularized tissues are those prepared by decellularizing biological tissues selected from the group consisting of pericardium, bladder, amnion, dura mater, peritoneum, diaphragm, fascia, small intestine submucosa and skin, wherein the biocompatible polymer and the decellularized tissue are complexed to each other, and wherein the substitute biomembrane reduces adhesion to biological tissues.

24. The kit of claim 23 wherein the decellularized tissues are the ones prepared by treating biological tissues with a high hydrostatic pressure or with a surfactant.

25. The kit of claim 24 wherein the treatment with a high hydrostatic pressure comprises applying a hydrostatic pressure of 50 to 1,500 MPa to biological tissues in a medium.

26. The kit of any one of claim 23 wherein the biocompatible polymer is fibrin glue.

27. The kit of claim 23 wherein the complexation of the biocompatible polymer to the decellularized tissues is immersion or coating of the biocompatible polymer to the decellularized tissues.

28. The kit of any one of claim 23 wherein a film thickness of the substitute biomembrane is 10 to 5,000 μm.

Assignees

• Km Biologics Co Ltd
• Adeka Corp
• Univ Nat Corp Tokyo Medical & Dental
• Univ Sapporo Medical

Inventors

• Saga Hideki
• Uchida Takanori
• Tokorozaki Shoko
• Hiwatari Ken-Ichiro
• Obara Haruki
• Kishida Akio
• Kimura Tsuyoshi
• Negishi Jun
• Higami Tetsuya
• Funamoto Seiichi

Classifications

• A61L31/005

  Ingredients of undetermined constitution or reaction products thereof · CPC title

• A61L31/046 Primary

  Fibrin; Fibrinogen · CPC title

• A61L31/10

  Macromolecular materials · CPC title

• A61L24/106

  Fibrin; Fibrinogen · CPC title

• A61L2300/424

  Anti-adhesion agents · CPC title